Skip to main content
main-content

01.12.2017 | Letter to the Editor | Ausgabe 1/2017 Open Access

Journal of Hematology & Oncology 1/2017

Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia

Zeitschrift:
Journal of Hematology & Oncology > Ausgabe 1/2017
Autoren:
Lili Tao, Qingshu Zeng, June Li, Miao Xu, Jiajia Wang, Ying Pan, Huiping Wang, Qianshan Tao, Yang Chen, Jun Peng, Ming Hou, Arend Jan Gerard Jansen, Heyu Ni, Zhimin Zhai
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13045-017-0413-3) contains supplementary material, which is available to authorized users.
Abbreviations
AA
Aplastic anemia
AML
Acute myeloid leukemia
CR
Complete responder
CTD
Connective tissue disease
ECL
Erythrina cristagalli lectin
FITC
Fluorescein isothiocyanate
ITP
Immune thrombocytopenia
IVIG
Intravenous immunoglobulin G
MAIPA
Monoclonal antibody immobilization of platelet antigen assay
MDS
Myelodysplastic syndrome
NR
Non-responder
PRP
Platelet-rich plasma
R
Responder
RCA-1
Ricinus communis agglutinin I

Introduction

Immune thrombocytopenia (ITP) is a common clinical bleeding disorder characterized by an immune-mediated clearance of autologous platelets, predominantly through autoantibodies targeting platelet surface receptors GPIIbIIIa and/or GPIb-IX and clearance by phagocytic cells in the reticuloendothelial system via Fcγ-receptors [14]. Low platelet counts place ITP patients at risk for severe bleeding including fatal intracranial hemorrhage. Most therapies for ITP including first-line corticosteroids and immunoglobulin G (IVIG), and last resort splenectomy, mainly target the Fc-dependent clearance pathway via blocking/attenuating Fc-Fcγ-R interaction or removal of putative site of platelet clearance [4]. However, the pathogenesis and mechanisms of therapies remain poorly understood and around 15–20% of ITP patients are inexplicably refractory to first-line therapies, and around 10% are refractory to splenectomy [5, 6]. In recent years, murine models and large cohort human studies report antibody specificity (i.e., anti-GPIIbIIIa versus anti-GPIb-IX) may play a significant role in dictating response to therapy in ITP [79]; whereby presence of anti-GPIb-IX antibodies results in decreased response to corticosteroids and IVIG [79]. Most recently, we reported that anti-GPIbα and some anti-GPIIbIIIa antibodies in humans induced platelet desialylation leading to Fc-independent platelet clearance in the liver via hepatic asialoglycoprotein Ashwell-Morell receptors [10], suggesting antibody-mediated desialylation may be one of the underlying mechanisms behind resistance to standard ITP therapies [8, 9, 11].
In the present study, we sought to address whether increased platelet desialylation was correlated with decreased response to treatment in ITP patients (Additional file 1: Supplementary Material). The platelets of randomly and consecutively enrolled 61 patients diagnosed with primary ITP were tested for desialylation prior to the indicated treatments (Table 1). Fluorescein-conjugated lectins Ricinus communis agglutinin I (RCA-1) and Erythrina cristagalli lectin (ECL) were used to detect desialylated galactose and β-GlcNAc residues via flow cytometry. We found the platelets of ITP patients had significantly higher desialylation as measured by both RCA-1 and ECL binding compared to those of healthy blood donors (p < 0.05) (Fig. 1). The 61 ITP patients subsequently underwent standard first-line therapy independent of platelet desialylation and MAIPA assays. After 1 month of treatment, there were 26 complete responders (CR), 21 responders (R), and 14 non-responders (NR) (Table 1). Retrospective data analysis using Kruskal-Wallis rank sum test revealed NR patients had significantly higher platelet desialylation, as compared to the CR and R groups (p < 0.01). Correlation analysis indicated that efficacy and the desialylation level are related (RCA-1 r = 0.395, p < 0.01; ECL r = 0.391, p < 0.01). The higher desialylation, the poorer the efficacy of therapy observed.
Table 1
Platelet desialylation of different groups [M (P 25, P 75)]
 
Age
Gender (M/F)
PLT (×109/L)
RCA-1 (%)
ECL (%)
ITP (n = 61)
43 ± 18
18/43
16.0 ± 12.5
1.60 (0.50,8.50)
1.30 (0.30,5.05)
 Efficacy grouping (n = 61)
  CR (n = 26)
36 ± 16
4/22
16.1 ± 15.3
1.10 (0.30,2.05)
0.85 (0.28,1.90)
  R (n = 21)
44 ± 19
10/11
17.2 ± 10.5
1.80 (0.65,5.75)
1.00 (0.30,2.05)
  NR (n = 14)
52 ± 17
4/10
13.9 ± 9.7
32.95 (4.40,62.20)
20.60 (2.83,34.68)
 Antibody grouping (n = 33)
  Anti-GPIbα (+) (n = 9)
39 ± 14
2/7
10.7 ± 5.3
2.50 (0.55,24.15)
2.20 (0.45,13.85)
  Single anti-GPIIbIIIa (+) (n = 14)
35 ± 16
3/11
16.0 ± 14.5
0.55 (0.18,1.70)
0.35 (0.10,1.90)
  Double negative (n = 10)
41 ± 17
5/5
14.9 ± 9.7
0.65 (0.10,5.50)
1.15 (0.10,2.15)
CTD (n = 10)
43 ± 20
3/7
20.3 ± 20.0
5.15 (1.63,28.85)
2.20 (0.90,14.25)
MDS (n = 10)
51 ± 27
3/7
29.3 ± 18.4
8.75 (1.30,14.03)
5.60 (2.08,16.85)
AA (n = 6)
31 ± 11
4/2
28.2 ± 9.6
0.75 (0.18,18.3)
0.95 (0.10,3.05)
AML (n = 8)
49 ± 19
4/4
19.4 ± 18.6
0.20 (0.13,0.80)
0.03 (0.01,0.50)
Healthy control (n = 20)
41 ± 12
10/10
197.7 ± 61.7
0.10 (0.10,0.30)
0.00 (0.00,0.10)
The platelets of primary ITP patients were collected prior to treatment. Fluorescin-conjugated lectins RCA-1 and ECL were used to detect desialylated galactose and β-GlcNAc residues on platelets via flow cytometry. Platelets from healthy blood donors (controls) and secondary ITP and non-ITP thrombocytopenic patients were also studied. Normal distribution measurement data is presented as mean ± SEM; skewed distribution measurement data is presented as M (P 25, P 75), in which M represents the median, P 25 and P 75 represent the 25th percentile and 75th percentile, respectively. Kruskal-Wallis rank sum test showed platelet desialylation is significantly higher in ITP patients as compared to that in healthy blood donors (RCA-1 Z = −4.918, p < 0.001; ECL Z = −5.512, p < 0.001). The course of therapies was independent from the platelet desialylation assays. The RCA-1 and ECL-positive platelets in non-responder (NR) group are significantly higher than those in complete responder (CR) and responder (R) groups (RCA-1 χ2 = 10.581, p < 0.01; ECL χ2 = 13.741, p < 0.005). No significant difference was observed between CR and R groups (p > 0.05). Correlation analysis indicated that as platelet desialylation increases, the efficacy of therapy decreases. Higher platelet desialylation in ITP patients with anti-GPIbα antibodies was observed as compared with other ITP patients although statistical difference was not reached (RCA-1 χ2 = 3.729, 0.16 > p > 0.05; ECL χ2 = 3.864, 0.15 > p > 0.05). Higher levels of platelet desialylation were also observed in patients of CTD (systemic lupus erythematosus, n = 6; sicca syndrome, n = 4) with thrombocytopenia; MDS and AA as compared with healthy controls (RCA-1 χ2 = 33.790, p < 0.001; ECL χ2 = 42.992, p < 0.001). There is no statistical difference in platelet desialylation between the AML patients and healthy donors (p > 0.05)
To test whether the presence of anti-GPIbα antibodies is associated with the platelet desialylation, we detected antibody using MAIPA in the available 33 patient samples collected prior to treatment. We observed a two- to sixfold increased platelet desialylation in patients with anti-GPIbα antibodies (n = 9) compared to that in patients with anti-GPIIbIIIa (n = 14) or without detectable antibodies (n = 10) (Table 1 and Fig. 1B). However, statistical significance was not reached, which is likely due to small sample size. Future larger studies should be useful in determining direct correlation between anti-GPIbα antibody positivity with platelet desialylation.
Interestingly, we also observed significant platelet desialylation in patients with non-ITP thrombocytopenias including connective tissue diseases (CTD), myelodysplastic syndrome (MDS), and aplastic anemia (AA) (p < 0.001) but not acute myeloid leukemia (AML) compared to healthy controls (Table 1 and Fig. 1B). Notably, although RCA-1 and ECL measures different types of deglycosylation, we did not observe significant difference between these two assays, suggesting either of them can be used for the potential diagnosis and prognosis.
In summary, our data demonstrates for the first time that the higher level of platelet desialylation is correlated with non-response to the first-line ITP therapies (likely also splenectomies; Additional file 1: Supplementary Material). These findings not only suggest that platelet desialylation is a useful biomarker in predicting response to treatment in clinical ITP but positions sialidase inhibitors, such as Tamiflu [12], as a potential novel therapeutic in the treatment of ITP as well as other thrombocytopenias.

Acknowledgements

The authors would like to thank Mr. Thomas McKeown, Miss Xun Fu, and Miss Jade Sullivan for editing the manuscript.

Funding

This work was supported by the Canadian Institutes of Health Research (MOP 97918, MOP 119540, MOP 119551); Canadian Blood Services-Canadian Institutes of Health Research partnership fund (CIHR-BUC201403-HN-326400); by the Special Research Funding for the Doctoral Program (NO. 20103420110001), Ministry of Education, People’s Republic of China; and by the Foundation of the Second Affiliated Hospital and the Hematological Research Center, Anhui Medical University, People’s Republic of China. June Li is a recipient of Ph.D. Graduate Fellowship from Canadian Blood Services. Miao Xu is a recipient of the State Scholarship Fund from the China Scholarship Council and Ontario Trillium Scholarship, Canada.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions

LT planned and carried out the experiments, analyzed the data, and prepared the manuscript. QZ supervised the clinical studies and analyzed the data. LJ and MX analyzed the data and prepared the manuscript. JW, YP, HW, QT, and YC carried out the experiments and analyzed the data. AJGJ, JP, and MH joined the international collaboration group meetings, analyzed the data and contributed to the preparation of manuscript. HN and ZZ (PIs) supervised the research, analyzed the data, and prepared the manuscript. LT and QZ contributed equally to this work and should be acknowledged as co-first authors. Both Dr. HN and Dr. ZZ should be acknowledged as co-corresponding authors. All authors read and approved the final manuscript.

Authors’ information

The contact information for the corresponding authors:
Heyu Ni, M.D.; Ph.D, Professor, Department of Laboratory Medicine and Pathobiology, Department of Medicine, and Department of Physiology, University of Toronto; Scientist of Canadian Blood Services Centre for Innovation; Platform Director for Hematology, Cancer and Immunological Diseases, St. Michael’s Hospital, Room 420, LKSKI - Keenan Research Centre, 209 Victoria Street, Toronto, Ontario, M5B 1W8, CANADA. Tel: 1-416-847-1738; Email: nih@smh.ca
Zhimin Zhai, M.D.; PhD. Professor, Director of Department of Hematology, The Second Affiliated Hospital and the Hematological Research Center, Anhui Medical University, Hefei 230601, China. Tel: 86-138-5514-7434; Email: zzzm889@163.com

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study has been approved by the Ethic Board of Anhui Medical University (No. 20131038). Patients in this study all signed informed consents to clinical data use at enrolment.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Zusatzmaterial
Additional file 1: Supplementary Material. (DOCX 49 kb)
13045_2017_413_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Journal of Hematology & Oncology 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise